AstraZeneca's Lynparza Gets Breakthrough Therapy Status

AstraZeneca's Lynparza Gets Breakthrough Therapy Status

AstraZeneca plcAZN announced that the FDA has granted Breakthrough Therapy designation to its PARP inhibitor, Lynparza (olaparib), for the monotherapy treatment of BRCA1/2 or ATM gene mutated metastatic castration resistant prostate cancer (mCRPC) …

(Visited 1 times, 1 visits today)
7
Like
Save

Comments

Comments are disabled for this post.